April 7, 2017 / 1:35 PM / in 6 months

BUZZ-Aurinia Pharma: Says one trial enough for kidney drug approval in 3 markets

** Aurinia shares up 7.7 pct at $7.10, set to snap 4-day losing streak, after Canadian co outlines path for kidney drug approval in the US, Europe and Japan

** Co says data from one planned late-stage trial as well as from its completed mid-stage study should support regulatory submissions in all three regions

** The drug, voclosporin, is being developed to treat lupus nephritis, an inflammation of the kidney

** About 750,000 AUPH shares traded, making them the 6th most active stock on the Nasdaq

** Up to Thursday’s close, stock had more than doubled in the last 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below